Abiomed stock falls 31 percent after the Danvers company says it’s under federal investigation

Shares of Abiomed Inc. plunged by nearly one-third on the Nasdaq stock exchange Thursday after the Danvers company said it is the subject of a federal investigation.

In documents filed with the Securities and Exchange Commission, the cardiac device maker disclosed it has received a subpoena from the US attorney’s office seeking files related to the labeling and marketing of its Impella 2.5 heart pump.


“We are in the process of responding to the subpoena and intend to cooperate fully,” Abiomed said in the filing.

Abiomed’s shares closed Thursday at $13.61, down $6.21, or 31.33 percent, on the Nasdaq.

Robert Weisman

Robert Weisman can be reached at
Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of